Login to Your Account

BioCryst, Green Cross Entering Korean Peramivir License Deal

By Randall Osborne

Thursday, June 15, 2006
As the avian flu continues to move through Asia and threaten the rest of the world, BioCryst Pharmaceuticals Inc.'s Phase I neuraminidase inhibitor garnered a licensing deal with Green Cross Corp. in Korea, where testing of peramivir will yield data to supplement the U.S. results. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription